BEERSE, BELGIUM, Aug. 21, 2026 (GLOBE NEWSWIRE) — Johnson & Johnson today announced that the European Commission (EC) has approved an indication extension for TECVAYLI® (teclistamab) in combination with daratumumab for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior therapy. The approval introduces a new treatment option as early as second line for patients living with RRMM.